The Prior Authorization Trap: Why Healthcare AI’s Next Delivery Test Is Getting Care Approved

A doctor can find the tumor, order the scan, choose the drug, and write the referral. The patient can be willing. The science can be sound. The intervention can be covered in principle.

Presented By Our Partners

Then the care stops at a form.

Prior authorization is often described as paperwork, but that understates its power. It is one of the hidden control points in American medicine: a gate between a clinical recommendation and whether that recommendation becomes a completed test, procedure, therapy, medication, rehabilitation stay, or specialist visit. In a healthcare system trying to move from discovery to delivery, prior authorization is where “we know what should happen” often becomes “we are still waiting.”

That makes it one of the most important tests for healthcare AI in 2026. Not because the world needs a faster way to deny care. It does not. The test is whether AI can turn medical necessity, coverage rules, clinical documentation, and patient context into a faster, more transparent path to appropriate care.

If it succeeds, prior authorization becomes part of the delivery layer: a way to reduce ambiguity, gather the right evidence, explain decisions, and get patients to the next step sooner. If it fails, AI becomes a denial engine — a system that uses automation to make friction cheaper, faster, and harder to challenge.

That distinction matters because healthcare delivery is not the same thing as healthcare discovery. Discovery produces the knowledge. Delivery determines whether that knowledge reaches the patient.

The Gate After the Recommendation

The first AI problem in delivery is finding patients medicine keeps missing. That is the logic behind AI case finding: identifying the patient with an abnormal lab, an incidental imaging finding, a high-risk pattern in the chart, or a guideline-based therapy that never happened.

The next problem is navigation. Finding a patient is not enough if no one can get them through scheduling, referrals, benefits, follow-up, and trust. That is why clinical AI is moving from prediction toward navigation — from “this patient is high risk” to “this is the next action, and here is how to complete it.”

Prior authorization sits directly in that pathway. It is the payer-facing gate after the clinician’s recommendation but before the patient receives care. It asks whether a service is covered, medically necessary, appropriately documented, and aligned with plan rules. In theory, that can protect patients from unnecessary treatment and protect the system from waste. In practice, it often becomes a maze of portals, faxes, phone calls, missing criteria, delayed notices, unclear denials, and appeals that few patients ever file.

The numbers are not subtle.

In its 2025 prior authorization physician survey, the American Medical Association reported that 95 percent of physicians said prior authorization delays access to necessary care. Seventy-nine percent said it can lead patients to abandon a recommended course of treatment. Twenty-six percent reported that prior authorization had led to a serious adverse event for a patient. Practices completed an average of 40 prior authorizations per physician per week, consuming 13 hours of physician and staff time. Forty percent of physicians said they had staff working exclusively on prior authorization. Ninety-four percent said it increased physician burnout.

KFF’s January 2026 polling found the patient-side version of the same story. Thirty-two percent of insured adults said prior authorization was a major burden. When asked to choose the single biggest non-cost burden in getting healthcare, 34 percent chose prior authorization — higher than understanding a bill, getting an appointment, or finding an in-network provider. Among insured adults with chronic conditions, 39 percent ranked prior authorization as the single biggest burden.

Those are not just administrative complaints. KFF found that 47 percent of insured adults, and 57 percent of insured adults with chronic conditions, said an insurer had denied, delayed, or altered access to a healthcare service, treatment, or medication in the previous two years. Among those affected, about one-third said the experience had a major negative impact on mental health or finances, and about one-quarter said it had a major negative impact on physical health.

The system has treated this as background friction for years. In 2026, it is becoming a front-door test of whether healthcare AI can improve the flow of care rather than simply optimize the business process around care.

The 2026 Regulatory Clock

The reason this topic is moving now is not only AI hype. It is also infrastructure.

CMS’s Interoperability and Prior Authorization Final Rule, CMS-0057-F, requires impacted payers — including Medicare Advantage organizations, state Medicaid and CHIP programs, Medicaid managed care plans, CHIP managed care entities, and qualified health plan issuers on federally facilitated exchanges — to modernize parts of the prior authorization process.

Some operational requirements begin in 2026. Impacted payers must send prior authorization decisions within 72 hours for expedited requests and seven calendar days for standard requests, with some limits by payer type. Beginning in 2026, they must provide a specific reason when a prior authorization request is denied, regardless of whether the request came through a portal, fax, email, mail, phone, or another channel. They also must publicly report prior authorization metrics.

The deeper technical shift comes next. By January 1, 2027, impacted payers generally must implement a FHIR-based Prior Authorization API that can list covered items and services, identify documentation requirements, support prior authorization request and response, and communicate whether a request is approved, denied with a specific reason, or requires more information.

That is dry regulatory language with real operational meaning. Prior authorization has often been a black box. The new model pushes it toward a computable workflow: What is required? What evidence is missing? What decision was made? Why? What happens next?

CMS is trying to accelerate that transition before the deadline. On May 13, 2026, the agency announced 29 healthcare organizations joining its Electronic Prior Authorization Acceleration initiative. The early adopters include providers such as Cleveland Clinic, Providence, Rush University System for Health, Ochsner Health, and Tennessee Oncology; electronic health record companies including Epic, Oracle, MEDITECH, athenahealth, eClinicalWorks, and Modernizing Medicine; and networks including CommonWell, eHealth Exchange, Kno2, and b.well Connected Health. They join major payers that had already committed to working with CMS, including Aetna, Cigna, Elevance Health, Humana, UnitedHealthcare, and others.

CMS Administrator Mehmet Oz captured the central point in the announcement: prior authorization “won’t be fixed by technology alone.” That is exactly right. But technology can make the brokenness measurable. It can show where documentation fails, where handoffs stall, where decisions are opaque, and where care disappears.

The danger is that the same infrastructure can also make denial easier.

Automation Is Already Here

AI in prior authorization is not a future scenario. It is already in the claims review cycle.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

KFF’s 2026 brief on AI in prior authorization and claims review cited a National Association of Insurance Commissioners survey of 93 insurers in 16 states. Eighty-four percent of responding insurers across health insurance product lines reported using AI or machine learning for tasks such as utilization management, disease management, and prior authorization processes.

Insurers are not the only ones using AI. Providers are adding AI to revenue-cycle management, coding, billing, documentation, eligibility checks, claims preparation, and appeals. Patients are beginning to use AI-supported tools to understand denials and generate appeal letters. The entire claims review cycle is being automated from multiple directions at once.

That creates a strange arms race. Payers can use AI to review requests faster. Providers can use AI to submit more complete requests. Patients can use AI to challenge denials. Each side may be solving a real pain point. But if the underlying rules remain opaque, the result may simply be faster conflict.

The Medicare Advantage data show why this matters.

KFF reported that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024. About 4.1 million requests were denied in full or in part. Only 11.5 percent of denied requests were appealed. But when denials were appealed, 80.7 percent were fully or partly overturned.

That is the most important number in the story. It means many denials that survived the first step did not survive scrutiny. It also means most denied patients never reached that scrutiny at all.

A good AI system would see that as a quality problem. Why were so many appealed denials overturned? Were the original decisions based on missing information, outdated criteria, poor documentation, rigid rule interpretation, or flawed review? Which services, diagnoses, patient groups, plans, or providers were most affected? How much care was delayed before the reversal? How many patients gave up before appealing?

A bad AI system would see the same data and learn how to preserve the denial while reducing the cost of review.

That is the line healthcare has to hold.

Approval Intelligence, Not Denial Automation

The most useful AI in prior authorization may not be the system that “decides” the case. It may be the system that makes the case complete before it reaches the decision.

There is a difference between denial automation and approval intelligence.

Denial automation asks: How can we process more requests with fewer people?

Approval intelligence asks: What evidence is required for this medically necessary care to move forward, and how can we assemble it correctly the first time?

In practice, that means AI should help match the requested service to the payer’s coverage criteria; identify the precise clinical documentation needed; retrieve relevant chart evidence with source traceability; flag missing labs, imaging, notes, prior therapies, or guideline criteria; draft clinician-reviewable submissions; track request status; explain denials in plain language; and prepare a corrected resubmission or appeal when the denial reason is incomplete, inaccurate, or addressable.

The outcome measure is not “claims processed per hour.” It is completed appropriate care.

That framing changes the business case. A prior authorization tool that only reduces administrative cost for payers may be financially attractive, but it is not necessarily a healthcare delivery breakthrough. A tool that reduces time-to-approval for appropriate care, lowers abandonment, reduces staff hours, makes denial reasons intelligible, improves appeal quality, and audits inequity across patient groups is much closer to the thing medicine actually needs.

This is where AI can be genuinely useful. Much of prior authorization is a structured evidence problem wrapped in fragmented workflow. The payer needs specific criteria. The provider has pieces of the evidence in the electronic health record. The patient experiences the process as delay. The clinician experiences it as clerical drag. The insurer experiences it as utilization management. The current system often fails because those views do not meet in one transparent place.

AI is well suited to extracting, organizing, summarizing, and checking information. It is poorly suited to being an unaccountable judge of whether an individual patient deserves care.

That distinction should become a design principle.

The Human-in-the-Loop Problem

The phrase “human in the loop” sounds reassuring until the loop is examined.

A human reviewer can become a rubber stamp if the AI-generated summary is biased, incomplete, or framed toward denial. A clinician can be overwhelmed if the system surfaces too many false issues. A patient can be trapped if the denial letter gives a vague reason and no meaningful next step. A regulator can be satisfied by the existence of human review without knowing whether that review is independent, informed, timely, or clinically competent.

Stanford HAI’s policy brief on responsible AI in health insurance warned about this risk directly. AI can help automate clearly approvable requests and reduce administrative burden. It can also “supercharge” denials, weaken meaningful human review, and reproduce biased historical patterns if trained on data from a system where access has never been equal.

That is not a theoretical concern. Healthcare utilization data often reflect access, not need. If one group receives less care because of geography, language, disability, discrimination, network gaps, or cost barriers, a model trained on historical utilization may learn that lower care is normal. The same problem appears when cost is used as a proxy for health need. Lower spending can mean less access, not better health.

Prior authorization AI therefore needs more than accuracy testing. It needs outcome surveillance.

The system should be monitored for whether denial rates, missing-document rates, appeal outcomes, treatment delays, and abandonment differ by diagnosis, race, ethnicity, language, disability status, geography, payer type, and provider setting. It should track whether AI-assisted denials are more or less likely to be overturned. It should measure how often a clinical denial received meaningful human medical review. It should record whether the patient and clinician were told what evidence was missing and how to correct it.

A healthcare AI system that cannot answer those questions is not ready to sit at a gate where care can stop.

What Good Looks Like

The right version of AI-enabled prior authorization would feel almost boring.

A clinician orders a service. The system checks whether prior authorization is required. If it is, it identifies the relevant payer criteria and the needed documentation. It finds the supporting evidence in the chart, shows its sources, and asks the clinician to confirm. It flags what is missing before submission. It sends the request electronically. The patient can see that the request exists, where it stands, and what the expected timeframe is. If the request is denied, the denial includes a specific reason, the criteria used, the evidence considered, and the next corrective step. If an appeal is appropriate, the system drafts it from the record and guidelines, but a qualified human reviews it before submission.

That is not science fiction. It is a workflow problem. The building blocks are EHR integration, FHIR APIs, coverage criteria, clinical documentation, rules engines, language models, audit trails, and accountable humans.

The harder part is governance. The incentives must reward completed appropriate care, not just faster processing. A payer-facing tool should not be judged only by reduced spend. A provider-facing tool should not be judged only by increased reimbursement. A patient-facing tool should not make false promises about coverage. Every participant has a way to misuse AI if the metric is too narrow.

So the useful metrics are blunt:

• How long did it take from order to authorization decision?
• How often was the request approved the first time because the documentation was complete?
• How many denials included a specific, correct, actionable reason?
• How often were denials appealed?
• How often were appealed denials overturned?
• How many patients started the recommended treatment after authorization?
• How often did patients abandon care after delay or denial?
• How many staff hours were saved without increasing inappropriate denials?
• Did outcomes differ across patient groups?
• Were clinical denials reviewed by qualified humans?

Those are delivery metrics. They ask whether the patient moved forward.

The Next Healthcare Delivery Company

The most interesting companies in this space will not describe themselves as generic administrative automation. The stronger version is more specific: they will own high-friction approval pathways where the stakes are clinical, the criteria are complex, the documentation burden is high, and delays are costly.

Oncology is an obvious example. So are advanced imaging, specialty drugs, post-acute care, durable medical equipment, genetic testing, sleep medicine, behavioral health, cardiometabolic therapy, and chronic disease programs where patients already struggle to move from recommendation to action.

The opportunity is not merely to help a payer say yes or no faster. It is to build the connective tissue among clinical guidelines, payer rules, EHR evidence, patient status, and accountable review.

That is why prior authorization belongs in the same conversation as case finding, navigation, and closed-loop referrals. Each exposes a different failure point in the same chain. Case finding asks whether the patient is identified. Navigation asks whether the patient can move through the system. Referrals ask whether the handoff is completed. Prior authorization asks whether the system will permit the recommended care to happen.

A healthcare breakthrough that stalls at any of those points is not yet delivered.

The Real Test

The 2026 story is not that AI is entering prior authorization. It already has. The story is that healthcare now has to decide what kind of AI belongs there.

The wrong version will be fast, opaque, and cheap. It will turn coverage review into a black box with better software. It will make patients and clinicians fight machines they cannot see, trained on rules they cannot inspect, producing decisions they cannot meaningfully challenge.

The right version will be slower to design and harder to govern. It will automate approvals where the evidence is clear. It will strengthen documentation before submission. It will explain denials. It will preserve meaningful human review for clinical decisions. It will measure whether patients actually receive care. It will audit for inequity. It will treat an overturned denial not as a closed case, but as a signal that the system failed upstream.

That is the standard worth applying.

Healthcare AI does not prove itself by predicting who needs help. It proves itself when the patient receives the help. Prior authorization is one of the gates where that proof will either appear or vanish.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.